Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 7/20 | 0.60 |
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1079849 | 0.88 | EGLN3 (0.77) | EGLN3EGLN1 | |
| SCHEMBL1082458 | 0.86 | EGLN3 (0.59) | EGLN3EGLN1NR1I2TP53MAPT | |
| SCHEMBL1165228 | 0.86 | GAA (0.45) | EGLN3EGLN1NR1I2MEN1ALDH1A1 | |
| SCHEMBL1080932 | 0.76 | EGLN3 (0.75) | EGLN3EGLN1NR1I2 | |
| SCHEMBL1165374 | 0.76 | EGLN3 (0.58) | EGLN3EGLN1TP53ALDH1A1 | |
| SCHEMBL13620662 | 0.75 | EGLN3 (1.00) | EGLN3EGLN1MEN1ALDH1A1KMT2A | |
| SCHEMBL1080635 | 0.74 | EGLN3 (0.71) | EGLN3EGLN1 | |
| SCHEMBL1081707 | 0.74 | EGLN3 (0.74) | EGLN3EGLN1MAPTMEN1KMT2A | |
| SCHEMBL1165142 | 0.73 | GAA (0.45) | EGLN3NR1I2TP53MAPTMEN1 | |
| SCHEMBL1165086 | 0.72 | HSP90AA1 (0.47) | EGLN3NR1I2TP53MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxo Smith Kline LLC., a corporation | 2011-02-17 | — | — | US | claimed |
| EP-2273879-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2011-01-19 | — | — | EP | claimed |
| WO-2009134850-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-05 | — | — | WO | claimed |
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxo Smith Kline LLC., a corporation | 2011-02-17 | — | — | US | disclosed |
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxo Smith Kline LLC., a corporation | 2011-02-17 | — | — | US | disclosed |
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxo Smith Kline LLC., a corporation | 2011-02-17 | — | — | US | disclosed |
| EP-2273879-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009134850-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134850-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN1 6/4885NR1I2 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.